{"id":"rivastigmine-patch","safety":{"commonSideEffects":[{"rate":"10-15","effect":"Nausea"},{"rate":"5-10","effect":"Vomiting"},{"rate":"5-10","effect":"Diarrhea"},{"rate":"5-10","effect":"Abdominal pain"},{"rate":"5-10","effect":"Anorexia"},{"rate":"5-10","effect":"Dizziness"},{"rate":"5-10","effect":"Headache"},{"rate":"5-15","effect":"Application site erythema"}]},"_chembl":{"chemblId":"CHEMBL636","moleculeType":"Small molecule","molecularWeight":"250.34"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Rivastigmine inhibits both acetylcholinesterase and butyrylcholinesterase, enzymes responsible for degrading acetylcholine. By preventing acetylcholine breakdown, the drug increases acetylcholine concentration in the central nervous system, which enhances cognitive function and slows neurodegeneration in Alzheimer's disease and Parkinson's disease dementia. The transdermal patch formulation provides sustained drug delivery with improved tolerability compared to oral administration.","oneSentence":"Rivastigmine is a cholinesterase inhibitor that increases acetylcholine levels in the brain by blocking the enzyme that breaks it down.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:05:29.635Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Mild to moderate Alzheimer's disease"},{"name":"Mild to moderate Parkinson's disease dementia"}]},"trialDetails":[{"nctId":"NCT07464340","phase":"PHASE1","title":"Rivastigmine Transdermal Patches Bioequivalence and Adhesion Assessment","status":"COMPLETED","sponsor":"Zodiac Produtos Farmaceuticos S.A.","startDate":"2023-05-12","conditions":"Bioequivalence Study in Healthy Subjects","enrollment":68},{"nctId":"NCT04226248","phase":"PHASE3","title":"CHIEF-PD (CHolinesterase Inhibitor to prEvent Falls in Parkinson's Disease)","status":"COMPLETED","sponsor":"University of Bristol","startDate":"2020-01-02","conditions":"Parkinson Disease","enrollment":600},{"nctId":"NCT04366518","phase":"EARLY_PHASE1","title":"Toward a Computationally-Informed, Personalized Treatment for Hallucinations","status":"RECRUITING","sponsor":"Yale University","startDate":"2021-07-15","conditions":"Hallucinations, Auditory, Psychosis","enrollment":35},{"nctId":"NCT06702124","phase":"PHASE3","title":"A Phase 3 Study of Rotigotine in Combination with Rivastigmine in Mild to Moderate Alzheimer's Disease","status":"RECRUITING","sponsor":"I.R.C.C.S. Fondazione Santa Lucia","startDate":"2023-12-01","conditions":"Alzheimer Disease","enrollment":348},{"nctId":"NCT02989402","phase":"PHASE4","title":"A Phase IV Study to Evaluate Safety, Tolerability and Effectiveness of Rivastigmine Patch 15cm2 in Patients With Severe Dementia of the Alzheimer's Type.","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2018-12-31","conditions":"Alzheimer's Disease","enrollment":100},{"nctId":"NCT05768126","phase":"PHASE4","title":"Prediction of ECT Treatment Response and Reduction of Cognitive Side-effects Using EEG and Rivastigmine","status":"RECRUITING","sponsor":"UMC Utrecht","startDate":"2021-09-29","conditions":"Depressive Disorder","enrollment":100},{"nctId":"NCT05883124","phase":"PHASE1","title":"Rivastigmine Bioequivalence Trial With Multiple Applications of Transdermal Patches (9.5 mg/24 h)","status":"COMPLETED","sponsor":"SocraTec R&D GmbH","startDate":"2023-04-17","conditions":"Bioequivalence","enrollment":38},{"nctId":"NCT03840837","phase":"PHASE4","title":"Cholinergic Neurotransmission in Mobility and Cognition in Parkinson Disease","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2019-05-02","conditions":"Parkinson Disease, Parkinson Disease Dementia","enrollment":31},{"nctId":"NCT05853341","phase":"PHASE1","title":"Rivastigmine Bioequivalence Trial With Multiple Application of Transdermal Patches (13.3mg/24h)","status":"COMPLETED","sponsor":"Luye Pharma Group Ltd.","startDate":"2023-05-02","conditions":"Healthy","enrollment":48},{"nctId":"NCT04732182","phase":"NA","title":"Telerehabilitation Alzheimer's Disease Feasibility (TADF)","status":"UNKNOWN","sponsor":"Bright Cloud International Corp","startDate":"2022-02-16","conditions":"Alzheimer Disease, Healthy Aging","enrollment":14},{"nctId":"NCT03915626","phase":"EARLY_PHASE1","title":"Effect of Heat on Rivastigmine TDS Products","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2019-10-04","conditions":"Bioavailability","enrollment":7},{"nctId":"NCT02444637","phase":"PHASE4","title":"Open Label Trial of Rivastigmine Patch in Subjects With Mild to Moderate Stage AD Having Coexisting svCVD","status":"COMPLETED","sponsor":"National Neuroscience Institute","startDate":"2015-04","conditions":"Alzheimer Disease, CVA (Cerebrovascular Accident)","enrollment":100},{"nctId":"NCT04189666","phase":"PHASE1, PHASE2","title":"Rivastigmine Patch Compared to Melatonin Patch in Prevention of Postoperative Delirium","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2019-11-18","conditions":"Delirium","enrollment":180},{"nctId":"NCT03659435","phase":"PHASE1","title":"Rivastigmine Bioequivalence Trial With Multiple Application of Transdermal Patches (9.5mg/24h)","status":"COMPLETED","sponsor":"SocraTec R&D GmbH","startDate":"2018-08-22","conditions":"Bioequivalence","enrollment":58},{"nctId":"NCT02703636","phase":"PHASE4","title":"NextStep:Study to Evaluate Safety,Efficacy & Tolerability of Rivastigmine Patch in Mild to Moderate Alzheimer's Patients.","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2016-05-09","conditions":"Mild to Moderate Alzheimer's Disease","enrollment":118},{"nctId":"NCT01852110","phase":"PHASE2","title":"Efficacy and Safety of MK-7622 as Adjunct Therapy in Participants With Alzheimer's Disease (MK-7622-012)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-10-22","conditions":"Alzheimer's Disease","enrollment":240},{"nctId":"NCT03573050","phase":"PHASE1","title":"Rivastigmine BA Trial With Multiple Application of Transdermal Patches, Adaptation and Tapering Phase","status":"COMPLETED","sponsor":"SocraTec R&D GmbH","startDate":"2018-05-16","conditions":"Bioequivalence","enrollment":36},{"nctId":"NCT02623764","phase":"","title":"EEG-cholinergic Index and Clinical Response to Treatment With Cholinesterase Inhibitors","status":"UNKNOWN","sponsor":"Landspitali University Hospital","startDate":"2015-12","conditions":"Alzheimer´s Disease","enrollment":218},{"nctId":"NCT01585272","phase":"PHASE4","title":"Tolerability of Rivastigmine Before and After Switching From Oral Formulation to Transdermal Patch in Alzheimer's Dementia","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-08","conditions":"Alzheimer's Dementia","enrollment":121},{"nctId":"NCT01670526","phase":"PHASE3","title":"Rivastigmine Patch in Veterans With Cognitive Impairment Following TBI","status":"COMPLETED","sponsor":"VA Office of Research and Development","startDate":"2012-12","conditions":"Traumatic Brain Injury, Cognitive Impairment","enrollment":94},{"nctId":"NCT01380288","phase":"NA","title":"Cognitive Changes in Alzheimer's Disease Patients Associated With or Without White Matter Changes After Rivastigmine","status":"COMPLETED","sponsor":"Dong-A University","startDate":"2011-06","conditions":"Alzheimer's Disease","enrollment":300},{"nctId":"NCT00099242","phase":"PHASE3","title":"Efficacy and Safety of the Rivastigmine Transdermal Patch in Patients With Probable Alzheimer's Disease","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2003-11","conditions":"Alzheimer's Disease, Dementia, Alzheimer Type","enrollment":1040},{"nctId":"NCT01519271","phase":"PHASE4","title":"Mild Cognitive Impairment in Parkinson's Disease","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2011-12","conditions":"Parkinson's Disease, Mild Cognitive Impairment","enrollment":28},{"nctId":"NCT00731224","phase":"PHASE4","title":"Compliance and Tolerability of Rivastigmine Transdermal Patch 10 cm² in Patients With Probable Alzheimer's Disease.","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2008-07","conditions":"Alzheimer's Disease","enrollment":380},{"nctId":"NCT01602198","phase":"NA","title":"Study of Exelon Transdermal Patch in Amnestic Mild Cognitive Impairment Patients","status":"TERMINATED","sponsor":"The Cleveland Clinic","startDate":"2011-06","conditions":"Mild Cognitive Disorder, Mild Cognitive Impairment","enrollment":1},{"nctId":"NCT01047579","phase":"PHASE4","title":"A 12 Week, Multicenter, Open Label Evaluation of Caregiver Preference, Safety and Tolerability of Exelon® Patch (Rivastigmine Transdermal) in Patients With Alzheimer's Disease","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2010-04","conditions":"Alzheimer's Disease","enrollment":51},{"nctId":"NCT00219232","phase":"PHASE3","title":"An Open-label Extension to Evaluate the Efficacy and Safety of the Rivastigmine Transdermal Patch in Patients With Probable Alzheimer's Disease","status":"COMPLETED","sponsor":"Novartis","startDate":"2003-02","conditions":"Alzheimer's Disease","enrollment":868},{"nctId":"NCT01529619","phase":"PHASE4","title":"Efficacy, Safety and Tolerability of Rivastigmine Patch in Patients With Mild to Moderate Alzheimer's Disease Switched From Cholinesterase Inhibitors","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-03","conditions":"Alzheimer's Disease","enrollment":52},{"nctId":"NCT01614886","phase":"PHASE3","title":"Randomized, Double-blind Study to Evaluate the Tolerability of 2 Different Titration Methods of Rivastigmine Patch in AD Patients (MMSE 10-20)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-07","conditions":"Alzheimer's Disease","enrollment":216},{"nctId":"NCT01487317","phase":"PHASE3","title":"Rivastigmine in the Management of Delirium","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2011-06","conditions":"Delirium","enrollment":23},{"nctId":"NCT01312363","phase":"","title":"Study for the Tolerability of Exelon Patch (Rivastigmine) for Alzheimer's Disease (AD) Patients","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2009-06","conditions":"Alzheimer's Disease","enrollment":300},{"nctId":"NCT02413554","phase":"PHASE4","title":"Rivastigmine Patch Effect on the Post-operative Delirium in Patients at Risk of Dementia.","status":"COMPLETED","sponsor":"Chung-Ang University Hosptial, Chung-Ang University College of Medicine","startDate":"2013-04","conditions":"Delirium","enrollment":62},{"nctId":"NCT00835159","phase":"PHASE4","title":"Rivastigmine in the Treatment of Postoperative Delirium: a Pilot Clinical Trial","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2008-12","conditions":"Delirium, Postoperative Cognitive Dysfunction","enrollment":30},{"nctId":"NCT01399125","phase":"PHASE3","title":"A 24-Week Efficacy, Safety and Tolerability of Rivastigmine Patch Study in Patients With Probable Alzheimer's Disease","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2011-07","conditions":"Alzheimer's Disease","enrollment":501},{"nctId":"NCT00428389","phase":"PHASE3","title":"Safety of Switching From Donepezil to Rivastigmine Patch in Patients With Probable Alzheimer's Disease","status":"COMPLETED","sponsor":"Novartis","startDate":"2007-01","conditions":"Alzheimer's Disease","enrollment":262},{"nctId":"NCT01348282","phase":"PHASE4","title":"Efficacy and Safety of Two Pharmacologic Strategies on Neurocognitive Impairment in HIV Infection. The TRIANT-TE Study","status":"COMPLETED","sponsor":"Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia","startDate":"2011-05","conditions":"Neurocognitive Disturbance, HIV Infection","enrollment":33},{"nctId":"NCT00988117","phase":"PHASE4","title":"The Effects of the Rivastigmine Patch on Parkinson's Disease With Memory and/or Thinking Problems","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2010-04","conditions":"Parkinsons Disease With Dementia, Parkinsons Disease With Mild to Moderate Memory and/or Thinking Problems","enrollment":15},{"nctId":"NCT00423085","phase":"PHASE3","title":"Efficacy and Safety of Rivastigmine Transdermal Patch in Patients With Mild to Moderate Alzheimer's Disease","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2007-01","conditions":"Alzheimer's Disease","enrollment":859},{"nctId":"NCT00948766","phase":"PHASE4","title":"Effects of Rivastigmine Patch on Activities of Daily Living and Cognition in Patients With Severe Dementia of the Alzheimer's Type (ACTION) (Study Protocol CENA713DUS44, NCT00948766) and a 24 Week Open-label Extension to Study CENA713DUS44","status":"COMPLETED","sponsor":"Novartis","startDate":"2009-07","conditions":"Alzheimer's Disease","enrollment":716},{"nctId":"NCT00506415","phase":"PHASE3","title":"Comparative Efficacy, Safety, and Tolerability of Rivastigmine 10 and 15 cm^2 Patch in Patients With Alzheimer's Disease (AD) Showing Cognitive Decline","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2007-06","conditions":"Alzheimer Disease","enrollment":1584},{"nctId":"NCT00767091","phase":"PHASE3","title":"Study of Rivastigmine to Treat Parkinsonian Apathy Without Dementia","status":"COMPLETED","sponsor":"University Hospital, Lille","startDate":"2009-03","conditions":"Parkinson's Disease, Apathy, no Dementia","enrollment":40},{"nctId":"NCT00561392","phase":"PHASE4","title":"Clinical Effectiveness of 10 cm^2 Rivastigmine Patch in Patients With Alzheimer's Disease","status":"COMPLETED","sponsor":"Novartis","startDate":"2007-11","conditions":"Alzheimer's Disease","enrollment":208},{"nctId":"NCT01183806","phase":"PHASE3","title":"Effects of Exercise and Rivastigmine on Quality of Life of Alzheimer's Disease Patients","status":"COMPLETED","sponsor":"Federal University of Bahia","startDate":"2010-07","conditions":"Alzheimer Disease","enrollment":40},{"nctId":"NCT00881205","phase":"PHASE4","title":"Rivastigmine in Multiple Sclerosis Patients With Cognitive Impairment","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2009-04","conditions":"Multiple Sclerosis, Cognitive Impairment","enrollment":86},{"nctId":"NCT00623103","phase":"PHASE3","title":"Long-term Safety of Rivastigmine Capsule and Patch in Patients With Mild to Moderately-severe Dementia Associated With Parkinson's Disease (PDD)","status":"COMPLETED","sponsor":"Novartis","startDate":"2008-01","conditions":"Parkinson's Disease Dementia","enrollment":583},{"nctId":"NCT00622713","phase":"PHASE4","title":"A 24 Week, Multicenter, Open, Evaluation of the Clinical Effectiveness of the Once-daily 10 cm^2 Rivastigmine Patch Formulation in Patients With Probable Alzheimer's Disease (EXTRA)","status":"COMPLETED","sponsor":"Novartis","startDate":"2008-01","conditions":"Alzheimer's Disease","enrollment":228},{"nctId":"NCT00549601","phase":"PHASE4","title":"Convenience, Tolerability, and Safety of Change in the Administration of Rivastigmine From Capsules to a Transdermal Patch in Patients With Mild to Moderate Alzheimer's Disease","status":"COMPLETED","sponsor":"Novartis","startDate":"2007-09","conditions":"Alzheimer's Disease","enrollment":142},{"nctId":"NCT01025466","phase":"PHASE4","title":"Exelon Patch and Combination With Memantine Comparative Trial","status":"COMPLETED","sponsor":"Inha University Hospital","startDate":"2008-12","conditions":"Alzheimer's Disease","enrollment":206},{"nctId":"NCT00018278","phase":"PHASE4","title":"Electrophysiologic Measures of Treatment Response in Alzheimer Disease","status":"COMPLETED","sponsor":"US Department of Veterans Affairs","startDate":"1998-10","conditions":"Alzheimer Disease","enrollment":""}],"_emaApprovals":[],"_faersSignals":[{"count":6,"reaction":"CONFUSIONAL STATE"},{"count":5,"reaction":"FALL"},{"count":3,"reaction":"AGITATION"},{"count":3,"reaction":"DYSKINESIA"},{"count":3,"reaction":"MENTAL STATUS CHANGES"},{"count":3,"reaction":"TREMOR"},{"count":3,"reaction":"URINARY TRACT INFECTION"},{"count":2,"reaction":"BLOOD CHOLINESTERASE DECREASED"},{"count":2,"reaction":"CHOLINESTERASE INHIBITION"},{"count":2,"reaction":"CONSTIPATION"}],"_approvalHistory":[],"publicationCount":123,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["exelon patch","Exelon patch","Exelon®","Exelon Patch","ENA713, Exelon"],"phase":"marketed","status":"active","brandName":"Rivastigmine patch","genericName":"Rivastigmine patch","companyName":"Chung-Ang University Hosptial, Chung-Ang University College of Medicine","companyId":"chung-ang-university-hosptial-chung-ang-university-college-of-medicine","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Rivastigmine is a cholinesterase inhibitor that increases acetylcholine levels in the brain by blocking the enzyme that breaks it down. Used for Mild to moderate Alzheimer's disease, Mild to moderate Parkinson's disease dementia.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}